CORONAVIRUS: We know these are difficult and challenging times for everyone. We are currently switching over to telemedicine visits via phone or video. We will call you. Please do not come in for your appointment. As always, you can reach us by email with any questions or requests. Wishing you health and strength through these unusual times.

Solriamfetol may curb OSA-associated excessive daytime sleepiness

By Marilynn Larkin, December 11, 2018

Solriamfetol, an investigational norepinephrine-dopamine reuptake inhibitor, improved excessive daytime sleepiness associated with obstructive sleep apnea (OSA) in a phase 3 trial reported last month in Chest.

Click HERE for the full article on MDLinx. This same article also ran in Reuters Health and MD Alert.

Facebook Comments